Allan I. Levey

Allan I. Levey's AcademicInfluence.com Rankings

Allan I. Levey

Medical

#937

World Rank

#1207

Historical Rank

Neurology

#79

World Rank

#128

Historical Rank

medical Degrees

Download Badge

Medical

Why Is Allan I. Levey Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Allan I. Levey's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Central cholinergic pathways in the rat: An overview based on an alternative nomenclature (Ch1–Ch6) (1983) (2258)
Variant of TREM2 associated with the risk of Alzheimer's disease. (2013) (2004)
Cholinergic innervation of cortex by the basal forebrain: Cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (Substantia innominata), and hypothalamus in the rhesus monkey (1983) (1880)
Vitamin E and donepezil for the treatment of mild cognitive impairment. (2005) (1712)
Localization of neuronal and glial glutamate transporters (1994) (1689)
Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease (2011) (1656)
Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo (1996) (1492)
Selective loss of glial glutamate transporter GLT‐1 in amyotrophic lateral sclerosis (1995) (1464)
Analysis of shared heritability in common disorders of the brain (2016) (1385)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (1073)
Endoproteolysis of Presenilin 1 and Accumulation of Processed Derivatives In Vivo (1996) (1061)
A Common Variant on Chromosome 9p21 Affects the Risk of Myocardial Infarction (2007) (1013)
Distribution of cholinergic neurons in rat brain: Demonstrated by the immunocytochemical localization of choline acetyltransferase (1983) (960)
A common variant on chromosome 9p21 affects the risk of myocardial infarction. (2007) (795)
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction (2009) (790)
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm (2008) (765)
5-hmC–mediated epigenetic dynamics during postnatal neurodevelopment and aging (2011) (750)
Striatal dopamine nerve terminal markers in human, chronic methamphetamine users (1996) (730)
Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis (2016) (716)
Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease (2017) (693)
Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report (2019) (646)
Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. (1993) (616)
AMPA glutamate receptor subunits are differentially distributed in rat brain (1993) (597)
The origins of cholinergic and other subcortical afferents to the thalamus in the rat (1987) (595)
Dopamine Axon Varicosities in the Prelimbic Division of the Rat Prefrontal Cortex Exhibit Sparse Immunoreactivity for the Dopamine Transporter (1998) (583)
Atlas of cholinergic neurons in the forebrain and upper brainstem of the macaque based on monoclonal choline acetyltransferase immunohistochemistry and acetylcholinesterase histochemistry (1984) (568)
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. (1997) (562)
Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine (2002) (546)
Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: Light and electron microscopy (1995) (527)
Oxidative Modifications and Down-regulation of Ubiquitin Carboxyl-terminal Hydrolase L1 Associated with Idiopathic Parkinson's and Alzheimer's Diseases* (2004) (522)
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions (2010) (475)
D1 and D2 dopamine receptor mRNA in rat brain. (1991) (475)
Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. (1990) (448)
Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases* (2006) (448)
Implanted neural electrodes cause chronic, local inflammation that is correlated with local neurodegeneration (2009) (433)
Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. (1993) (426)
Anatomical and physiological evidence for D1 and D2 dopamine receptor colocalization in neostriatal neurons (2000) (424)
Activation of Metabotropic Glutamate Receptor 5 Has Direct Excitatory Effects and Potentiates NMDA Receptor Currents in Neurons of the Subthalamic Nucleus (2000) (415)
D1 dopamine receptor immunoreactivity in human and monkey cerebral cortex: predominant and extrasynaptic localization in dendritic spines. (1994) (396)
A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction (2006) (383)
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation (2019) (372)
Disruption of the m1 receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. (1997) (370)
Co-localization of acetylcholinesterase and choline acetyltransferase in the rat cerebrum (1983) (362)
Dopamine transporters and neuronal injury. (1999) (359)
Functional Interaction between Monoamine Plasma Membrane Transporters and the Synaptic PDZ Domain–Containing Protein PICK1 (2001) (345)
Muscarinic acetylcholine receptor expression in memory circuits: implications for treatment of Alzheimer disease. (1996) (330)
Immunocytochemical localization of the dopamine transporter in human brain (1999) (328)
Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease (2014) (317)
Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. (1995) (317)
Common genetic variants in the CLDN2 and PRSS1-PRSS2 loci alter risk for alcohol-related and sporadic pancreatitis (2012) (308)
Characterization of Central Inhibitory Muscarinic Autoreceptors by the Use of Muscarinic Acetylcholine Receptor Knock-Out Mice (2002) (306)
Loss of apolipoprotein E receptor LR11 in Alzheimer disease. (2004) (304)
Cholinergic and non-cholinergic septohippocampal pathways (1985) (303)
Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra (1997) (298)
Variant of TREM 2 Associated with the Risk of Alzheimer ’ s Disease (2012) (296)
A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer's Disease. (2017) (286)
Cholinergic systems in mammalian brain identified with antibodies against choline acetyltransferase (1984) (284)
Age‐related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys (1998) (280)
Choline acetyltransferase-immunoreactive neurons intrinsic to rodent cortex and distinction from acetylcholinesterase-positive neurons (1984) (279)
Oxidative Modifications and Aggregation of Cu,Zn-Superoxide Dismutase Associated with Alzheimer and Parkinson Diseases* (2005) (278)
Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. (2004) (276)
The Lipoprotein Receptor LR11 Regulates Amyloid β Production and Amyloid Precursor Protein Traffic in Endosomal Compartments (2006) (276)
Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease (2015) (275)
Common variants at MS 4 A 4 / MS 4 A 6 E , CD 2 AP , CD 33 and EPHA 1 are associated with late-onset Alzheimer ’ s disease (2011) (274)
Activation of the genetically defined m1 muscarinic receptor potentiates N-methyl-D-aspartate (NMDA) receptor currents in hippocampal pyramidal cells. (1998) (272)
Familial Parkinson's Disease-associated L166P Mutation Disrupts DJ-1 Protein Folding and Function* (2004) (268)
Substance P-Containing terminals in synaptic contact with cholinergic neurons in the neostriatum and basal forebrain: a double immunocytochemical study in the rat (1986) (268)
Monoclonal antibodies to choline acetyltransferase: production, specificity, and immunohistochemistry (1983) (265)
Dopaminergic Neurons Intrinsic to the Primate Striatum (1997) (262)
Proteomic Characterization of Postmortem Amyloid Plaques Isolated by Laser Capture Microdissection*[boxs] (2004) (260)
Evidence for brain glucose dysregulation in Alzheimer's disease (2018) (258)
Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission. (1993) (247)
The Mount Sinai cohort of large-scale genomic, transcriptomic and proteomic data in Alzheimer's disease (2018) (242)
Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease (1999) (241)
RGS2 Binds Directly and Selectively to the M1 Muscarinic Acetylcholine Receptor Third Intracellular Loop to Modulate Gq/11α Signaling* (2004) (240)
A light and electron microscopic procedure for sequential double antigen localization using diaminobenzidine and benzidine dihydrochloride. (1986) (239)
U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease (2013) (236)
Biochemical Characterization and Localization of a Non‐N‐Methyl‐D‐Aspartate Glutamate Receptor in Rat Brain (1992) (231)
Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats (2008) (228)
Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease (1996) (224)
A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning (2009) (221)
Differential Regulation of Molecular Subtypes of Muscarinic Receptors in Alzheimer's Disease (1995) (220)
Vesicular Localization and Activity-Dependent Trafficking of Presynaptic Choline Transporters (2003) (215)
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine (2004) (214)
Distinct interneuron types express m2 muscarinic receptor immunoreactivity on their dendrites or axon terminals in the hippocampus (1997) (213)
Complex relationship between Parkin mutations and Parkinson disease. (2002) (212)
Loss of basal forebrain P75NTR immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease (2002) (209)
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. (2012) (208)
Dopamine D5 receptor immunolocalization in rat and monkey brain (2000) (206)
Variants with large effects on blood lipids and the role of cholesterol and triglycerides in coronary disease (2016) (202)
Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology (2016) (201)
Cholinergic nucleus basalis neurons may influence the cortex via the thalamus (1987) (200)
Four distinct trajectories of tau deposition identified in Alzheimer’s disease (2021) (200)
Immunochemical analysis of dopamine transporter protein in Parkinson's disease (1997) (197)
Genome-wide association study identifies a sequence variant within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm (2010) (197)
Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) (196)
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2019) (194)
Tau pathology in a family with dementia and a P301L mutation in tau. (1999) (187)
Elevated serum pesticide levels and risk for Alzheimer disease. (2014) (185)
Immunochemical Analysis of Vesicular Monoamine Transporter (VMAT2) Protein in Parkinson's Disease (1999) (183)
Delta-secretase cleaves amyloid precursor protein and regulates the pathogenesis in Alzheimer's disease (2015) (183)
Increased MPTP Neurotoxicity in Vesicular Monoamine Transporter 2 Heterozygote Knockout Mice (1998) (179)
Mild cognitive impairment: an opportunity to identify patients at high risk for progression to Alzheimer's disease. (2006) (177)
Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues. (1991) (174)
Autosomal recessive causes likely in early-onset Alzheimer disease. (2012) (172)
Light and Electron Microscopic Localization of Presenilin-1 in Primate Brain (1997) (172)
Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users (1996) (171)
Polyubiquitin Linkage Profiles in Three Models of Proteolytic Stress Suggest the Etiology of Alzheimer Disease* (2011) (169)
Glycogen synthase kinase 3β and Alzheimer’s disease: pathophysiological and therapeutic significance (2006) (167)
Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia (1999) (166)
Localization of metabotropic glutamate receptor 7 mRNA and mGluR7a protein in the rat basal ganglia (1999) (164)
Cholinergic vs. noncholinergic efferents from the mesopontine tegmentum to the extrapyramidal motor system nuclei (1988) (164)
Differential expression of D1 and D2 dopamine and m4 muscarinic acetylcholine receptor proteins in identified striatonigral neurons (1997) (163)
Role of Presynaptic Muscarinic and GABAB Receptors in Spinal Glutamate Release and Cholinergic Analgesia in Rats (2002) (162)
Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE (2015) (161)
Microengineered human blood–brain barrier platform for understanding nanoparticle transport mechanisms (2020) (159)
Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. (2012) (158)
Hyperaccumulation of FAD-linked presenilin 1 variants in vivo (1997) (147)
Alterations in Glutamate Transporter Protein Levels in Kindling‐Induced Epilepsy (1997) (146)
Proteomic identification of novel proteins associated with Lewy bodies. (2008) (145)
Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. (2002) (145)
Rab11a and Myosin Vb Regulate Recycling of the M4Muscarinic Acetylcholine Receptor (2002) (144)
Localization of muscarinic M3 receptor protein and M3 receptor binding in rat brain (1994) (143)
Late-life depression as a risk factor for mild cognitive impairment or Alzheimer's disease in 30 US Alzheimer's disease centers. (2012) (140)
Meta-Analysis of the Alzheimer’s Disease Human Brain Transcriptome and Functional Dissection in Mouse Models (2020) (140)
Effects of multiple genetic loci on age at onset in late-onset Alzheimer disease: a genome-wide association study. (2014) (140)
A Meta-Analysis of Alzheimer's Disease Incidence and Prevalence Comparing African-Americans and Caucasians. (2015) (139)
Activation of Group II Metabotropic Glutamate Receptors Inhibits Synaptic Excitation of the Substantia Nigra Pars Reticulata (2000) (138)
Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (136)
LR11/SorLA Expression Is Reduced in Sporadic Alzheimer Disease but not in Familial Alzheimer Disease (2006) (135)
Chapter 5 Cholinergic innervation and receptors in the cerebellum (1997) (135)
Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s Disease (2018) (135)
Choline acetyltransferase immunoreactivity in the rat thalamus (1987) (134)
Pre- and postsynaptic localization of GABAB receptors in the basal ganglia in monkeys (1999) (131)
A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors (2010) (126)
Days to criterion as an indicator of toxicity associated with human Alzheimer amyloid‐β oligomers (2010) (126)
Light and electron microscopic study of m2 muscarinic acetylcholine receptor in the basal forebrain of the rat (1995) (125)
Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease (2013) (125)
Mild cognitive impairment in Parkinson's disease: subtypes and motor characteristics. (2010) (125)
Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) (123)
Loss of LR11/SORLA Enhances Early Pathology in a Mouse Model of Amyloidosis: Evidence for a Proximal Role in Alzheimer's Disease (2008) (122)
TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions (2014) (119)
Cell-specific Sorting of Biogenic Amine Transporters Expressed in Epithelial Cells* (1996) (119)
TREM2 is associated with increased risk for Alzheimer’s disease in African Americans (2015) (116)
Eye Tracking During a Visual Paired Comparison Task as a Predictor of Early Dementia (2009) (115)
The zinc transporter ZnT3 interacts with AP-3 and it is preferentially targeted to a distinct synaptic vesicle subpopulation. (2003) (114)
Deletion of M1 Muscarinic Acetylcholine Receptors Increases Amyloid Pathology In Vitro and In Vivo (2010) (114)
Subcellular Redistribution of m2 Muscarinic Acetylcholine Receptors in Striatal Interneurons In Vivo after Acute Cholinergic Stimulation (1998) (112)
Nigrostriatal collaterals to thalamus degenerate in parkinsonian animal models (2001) (111)
Muscarinic m1 and m2 receptor proteins in local circuit and projection neurons of the primate striatum: Anatomical evidence for cholinergic modulation of glutamatergic prefronto‐striatal pathways (2001) (109)
Multiple Effects of Aspartate Mutant Presenilin 1 on the Processing and Trafficking of Amyloid Precursor Protein* (2001) (109)
Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease. (2016) (108)
Transgenic mice overexpressing reticulon 3 develop neuritic abnormalities (2007) (107)
Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age (2019) (106)
Pharmacologic Inhibition of ROCK2 Suppresses Amyloid-β Production in an Alzheimer's Disease Mouse Model (2013) (106)
A proteomic network approach across the ALS‐FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain (2017) (105)
Cellular and subcellular localization of the dopamine transporter in rat cortex. (1998) (105)
Interaction of Akt-phosphorylated SRPK2 with 14-3-3 Mediates Cell Cycle and Cell Death in Neurons* (2009) (105)
Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases (2012) (104)
Integrating human brain proteomes with genome-wide association data implicates new proteins in Alzheimer’s disease pathogenesis (2021) (103)
Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach. (2014) (103)
Neuronal LR11/sorLA expression is reduced in mild cognitive impairment (2007) (102)
Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer’s disease (2019) (101)
Muscarinic receptor subtypes involved in hippocampal circuits. (1999) (100)
Coaggregation of RNA-Binding Proteins in a Model of TDP-43 Proteinopathy with Selective RGG Motif Methylation and a Role for RRM1 Ubiquitination (2012) (100)
Cholinergic innervation and receptors in the cerebellum. (1997) (100)
D 1 and D 2 dopamine receptor mRNA in rat brain ( striatum / substantia nigra / amygdala / septum / in situ hybridization ) (100)
Polarized Expression of the Antidepressant-Sensitive Serotonin Transporter in Epinephrine-Synthesizing Chromaffin Cells of the Rat Adrenal Gland (1997) (99)
M1 Muscarinic Acetylcholine Receptors Activate Extracellular Signal-Regulated Kinase in CA1 Pyramidal Neurons in Mouse Hippocampal Slices (2001) (99)
Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP (2013) (97)
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (96)
Conserved brain myelination networks are altered in Alzheimer's and other neurodegenerative diseases (2018) (96)
Association of GSK3B with Alzheimer disease and frontotemporal dementia. (2008) (96)
Very early activation of m-calpain in peripheral nerve during Wallerian degeneration (2002) (95)
Huntingtin-associated Protein 1 Interacts with Hepatocyte Growth Factor-regulated Tyrosine Kinase Substrate and Functions in Endosomal Trafficking* (2002) (95)
Multiplex SILAC Analysis of a Cellular TDP-43 Proteinopathy Model Reveals Protein Inclusions Associated with SUMOylation and Diverse Polyubiquitin Chains* (2010) (94)
High Blood Pressure and Cognitive Decline in Mild Cognitive Impairment (2013) (94)
GABAB and group I metabotropic glutamate receptors in the striatopallidal complex in primates (2000) (91)
Down‐Regulation of AMPA Receptor Subunit GluR2 in Amygdaloid Kindling (1995) (90)
Localization of M2 muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus (2000) (90)
Endogenous Presenilin-1 Targets to Endocytic Rather Than Biosynthetic Compartments (2000) (89)
Phosphoproteomic analysis of human brain by calcium phosphate precipitation and mass spectrometry. (2008) (88)
Distribution and Developmental Regulation of Metabotropic Glutamate Receptor 7a in Rat Brain (1998) (88)
Rab5-dependent Trafficking of the m4 Muscarinic Acetylcholine Receptor to the Plasma Membrane, Early Endosomes, and Multivesicular Bodies* (2001) (87)
An assessment by the Statin Cognitive Safety Task Force: 2014 update. (2014) (87)
Transgenic Rescue of ataxia Mice with Neuronal-Specific Expression of Ubiquitin-Specific Protease 14 (2006) (86)
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. (2020) (86)
Development of a rapid screening instrument for mild cognitive impairment and undiagnosed dementia. (2008) (84)
Cortical inputs to m2‐immunoreactive striatal interneurons in rat and monkey (2000) (83)
Regulation of the Subcellular Distribution of m4 Muscarinic Acetylcholine Receptors in Striatal Neurons In Vivo by the Cholinergic Environment: Evidence for Regulation of Cell Surface Receptors by Endogenous and Exogenous Stimulation (1999) (82)
Proton Pump Inhibitors and Risk of Mild Cognitive Impairment and Dementia (2017) (81)
Association of Early-Onset Alzheimer Disease With Elevated Low-density Lipoprotein Cholesterol Levels and Rare Genetic Coding Variants of APOB. (2019) (81)
Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice (2017) (81)
Heptachlor alters expression and function of dopamine transporters. (1999) (81)
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. (2018) (81)
Large-scale deep multi-layer analysis of Alzheimer’s disease brain reveals strong proteomic disease-related changes not observed at the RNA level (2021) (80)
Tau-Mediated Disruption of the Spliceosome Triggers Cryptic RNA Splicing and Neurodegeneration in Alzheimer’s Disease (2019) (79)
Muscarinic acetylcholine receptor subtype, m2: diverse functional implications of differential synaptic localization. (1997) (79)
Daytime sleepiness and functional impairment in Alzheimer disease. (2007) (79)
Ionotropic and metabotropic GABA and glutamate receptors in primate basal ganglia (2001) (77)
Potassium channel Kv1.3 is highly expressed by microglia in human Alzheimer's disease. (2015) (77)
Munc18 Interacting Proteins (2003) (77)
Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer’s disease-related proteins (2018) (77)
Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer’s disease (2017) (77)
Regulation of muscarinic acetylcholine receptor function in acetylcholinesterase knockout mice (2003) (76)
The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link? (2012) (76)
Aggregates of Small Nuclear Ribonucleic Acids (snRNAs) in Alzheimer's Disease (2014) (75)
Proteomics analysis reveals novel components in the detergent-insoluble subproteome in Alzheimer's disease. (2009) (75)
Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration. (2010) (75)
Distribution of high affinity choline transporter immunoreactivity in the primate central nervous system (2003) (74)
Localization of the m2 muscarinic acetylcholine receptor protein and mRNA in cortical neurons of the normal and cholinergically deafferented rhesus monkey (1998) (74)
Non-coding variability at the APOE locus contributes to the Alzheimer’s risk (2019) (74)
Behavior Matters—Cognitive Predictors of Survival in Amyotrophic Lateral Sclerosis (2013) (73)
The role of muscarinic acetylcholine receptor‐mediated activation of extracellular signal‐regulated kinase 1/2 in pilocarpine‐induced seizures (2002) (73)
Analysis of a membrane‐enriched proteome from postmortem human brain tissue in Alzheimer's disease (2012) (73)
CHOLINERGIC THERAPIES IN ALZHEIMER'S DISEASE (1999) (72)
Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: implications for cholinergic-based therapies. (1995) (71)
Molecular and functional identification of m1 muscarinic acetylcholine receptors in rat ventricular myocytes. (1996) (71)
Development of transgenic rats producing human β-amyloid precursor protein as a model for Alzheimer's disease: Transgene and endogenous APP genes are regulated tissue-specifically (2008) (71)
Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns (2017) (69)
The production of monoclonal antibodies reactive with bovine choline acetyltransferase (1981) (69)
Differential Phagocytic Properties of CD45low Microglia and CD45high Brain Mononuclear Phagocytes—Activation and Age-Related Effects (2018) (67)
Association between polychlorinated biphenyls and Parkinson's disease neuropathology. (2012) (67)
Immunological detection of glutamate receptor subtypes in human central nervous system (1992) (67)
Quantitative phosphoproteomics of Alzheimer's disease reveals cross‐talk between kinases and small heat shock proteins (2015) (65)
Multiscale causal networks identify VGF as a key regulator of Alzheimer’s disease (2020) (65)
Dopamine axons in primate prefrontal cortex: specificity of distribution, synaptic targets, and development. (1998) (65)
The Dopamine Transporter Carboxyl-terminal Tail (1996) (64)
SPE-39 family proteins interact with the HOPS complex and function in lysosomal delivery. (2009) (64)
Altered striatal function and muscarinic cholinergic receptors in acetylcholinesterase knockout mice. (2003) (64)
Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer’s disease: preclinical proof of concept (2018) (63)
Choline acetyltransferase-like immunoreactivity in the forebrain of the red-eared pond turtle (Pseudemys scripta elegans) (1984) (63)
On the distribution patterns of D1, D2, tyrosine hydroxylase and dopamine transporter immunoreactivities in the ventral striatum of the rat (1999) (63)
Modulation of Renin‐Angiotensin System May Slow Conversion from Mild Cognitive Impairment to Alzheimer's Disease (2015) (63)
Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain (2020) (61)
Neuron enriched nuclear proteome isolated from human brain. (2013) (61)
Subcellular Localization of Presenilins: Association with a Unique Membrane Pool in Cultured Cells (2000) (60)
Infracortical interstitial cells concurrently expressing m2-muscarinic receptors, acetylcholinesterase and nicotinamide adenine dinucleotide phosphate-diaphorase in the human and monkey cerebral cortex (1998) (60)
Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans (2012) (59)
Interaction of Isoflurane with the Dopamine Transporter (2003) (59)
Distribution of Group III mGluRs in Rat Basal Ganglia with Subtype‐Specific Antibodies (1999) (58)
Rat dorsal root ganglia express m1-m4 muscarinic receptor proteins. (1999) (58)
Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer’s disease (2017) (58)
Quantitative analysis of the detergent-insoluble brain proteome in frontotemporal lobar degeneration using SILAC internal standards. (2012) (57)
Diverse pre- and post-synaptic expression of m1-m4 muscarinic receptor proteins in neurons and afferents in the rat neostriatum. (1995) (57)
Effects of Hypertension and Hypercholesterolemia on Cognitive Functioning in Patients With Alzheimer Disease (2008) (57)
5-Hydroxymethylation-associated epigenetic modifiers of Alzheimer's disease modulate Tau-induced neurotoxicity. (2016) (56)
Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (56)
Muscarinic Activation of Mitogen‐Activated Protein Kinase in PC12 Cells (2000) (56)
Development of muscarinic receptor subtypes in the forebrain of the mouse (1995) (55)
Event-related potential changes in groups at increased risk for Alzheimer disease. (1999) (55)
Rho Kinase II Phosphorylation of the Lipoprotein Receptor LR11/SORLA Alters Amyloid-β Production* (2010) (55)
Cell-specific extracellular signal-regulated kinase activation by multiple G protein-coupled receptor families in hippocampus. (2003) (54)
Asparaginyl endopeptidase cleaves TDP‐43 in brain (2012) (54)
Recent Trends in Alzheimer Disease Mortality in the United States, 1999 to 2004 (2009) (53)
The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (52)
Proteomics of protein post-translational modifications implicated in neurodegeneration (2014) (51)
Changes in the detergent‐insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression (2016) (51)
Rat Schwann cells express M1–M4 muscarinic receptor subtypes (2006) (50)
Mint3/X11γ Is an ADP-Ribosylation Factor-dependent Adaptor that Regulates the Traffic of the Alzheimer's Precursor Protein from the Trans-Golgi Network (2008) (49)
β-Hexachlorocyclohexane levels in serum and risk of Parkinson's disease. (2011) (48)
Factors Affecting Survival of Patients with Neurodegenerative Disease (2010) (48)
GGA1-mediated endocytic traffic of LR11/SorLA alters APP intracellular distribution and amyloid-β production (2012) (48)
Brain proteome-wide association study implicates novel proteins in depression pathogenesis (2021) (48)
Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-Dopa uptake and metabolism after intracerebral implantation in nonhuman primates. (1997) (48)
Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease (1999) (47)
Selective enrichment of DJ‐1 protein in primate striatal neuronal processes: Implications for Parkinson's disease (2007) (47)
Differential presynaptic and postsynaptic expression of m1–m4 muscarinic acetylcholine receptors at the perforant pathway/granule cell synapse (1998) (46)
Immunochemical Studies of Bovine and Human Choline‐O‐Acetyltransferase Using Monoclonal Antibodie (1982) (46)
Meta-analysis of the human brain transcriptome identifies heterogeneity across human AD coexpression modules robust to sample collection and methodological approach (2019) (46)
Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer’s disease (2020) (45)
Muscarinic receptor subtypes in the lateral geniculate nucleus: A light and electron microscopic analysis (1999) (45)
Statins and Cognitive Decline in Older Adults with Normal Cognition or Mild Cognitive Impairment (2013) (44)
Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts (2016) (44)
LSD1 protects against hippocampal and cortical neurodegeneration (2017) (44)
Presenilin‐1 protein expression in familial and sporadic Alzheimer's disease (1997) (44)
A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation (2017) (44)
Presenilin 1 Independently Regulates β-Catenin Stability and Transcriptional Activity* (2001) (44)
Proteomic analysis of postsynaptic density in Alzheimer's disease. (2013) (43)
Cortical Proteins Associated With Cognitive Resilience in Community-Dwelling Older Persons. (2020) (43)
Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging β-amyloid in Alzheimer’s disease (2006) (43)
Deficits in acetylcholine homeostasis, receptors and behaviors in choline transporter heterozygous mice (2007) (43)
Omics sciences for systems biology in Alzheimer’s disease: State-of-the-art of the evidence (2021) (42)
U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer’s disease due to autosomal dominant genetic mutations and trisomy 21 (2014) (42)
Selective expression of m2 muscarinic receptor in the parvocellular channel of the primate visual cortex. (1996) (42)
Cognitive Performance and Plasma Levels of Homocysteine, Vitamin B12, Folate and Lipids in Patients with Alzheimer Disease (2008) (42)
Cross-species and intraspecies reactivities of monoclonal antibodies against choline acetyltransferase (1982) (42)
Quantitative Analysis of the Brain Ubiquitylome in Alzheimer's Disease (2018) (42)
Bacterial expression of human muscarinic receptor fusion proteins and generation of subtype‐specific antisera (1990) (41)
A multiancestral genome-wide exome array study of Alzheimer disease, frontotemporal dementia, and progressive supranuclear palsy. (2015) (41)
Synaptic and extrasynaptic GABA-A and GABA-B receptors in the globus pallidus: An electron microscopic immunogold analysis in monkeys (2005) (41)
Alzheimer’s disease: A clinical perspective and future nonhuman primate research opportunities (2019) (41)
Notch Signaling Inhibits PC12 Cell Neurite Outgrowth via RBP-J-Dependent and -Independent Mechanisms (2002) (40)
Cultures of airway parasympathetic nerves express functional M2 muscarinic receptors. (1996) (40)
Stem cell-derived neurons reflect features of protein networks, neuropathology, and cognitive outcome of their aged human donors (2021) (40)
Rarity of the Alzheimer disease-protective APP A673T variant in the United States. (2015) (39)
Muscarinic receptor M2 in cat visual cortex: Laminar distribution, relationship to γ‐aminobutyric acidergic neurons, and effect of cingulate lesions (2001) (39)
Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau (2020) (38)
Integrating Next-Generation Genomic Sequencing and Mass Spectrometry To Estimate Allele-Specific Protein Abundance in Human Brain. (2017) (38)
Altered hippocampal muscarinic receptors in acetylcholinesterase‐deficient mice (2003) (38)
RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease (2018) (38)
Fas-associated factor 1 and Parkinson's disease (2008) (37)
Postnatal development of tyrosine hydroxylase- and dopamine transporter-immunoreactive axons in monkey rostral entorhinal cortex. (1998) (36)
Immunohistochemistry of choline acetyltransferase in the guinea pig brain (1988) (36)
The dysarthria—clumsy hand syndrome: A distinct clinical entity related to pontine infarction (1990) (36)
Mining Outcome-relevant Brain Imaging Genetic Associations via Three-way Sparse Canonical Correlation Analysis in Alzheimer’s Disease (2017) (36)
Effects of APOE Genotype on Brain Proteomic Network and Cell Type Changes in Alzheimer's Disease (2018) (36)
Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (35)
Differential subcellular and subsynaptic distribution of GABAA and GABAB receptors in the monkey subthalamic nucleus (2004) (35)
Novel Interaction between the M4 Muscarinic Acetylcholine Receptor and Elongation Factor 1A2* (2002) (35)
Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment (2020) (35)
Disease-Modifying Effects of M1 Muscarinic Acetylcholine Receptor Activation in an Alzheimer's Disease Mouse Model. (2017) (35)
An exploration of subgroups of mild cognitive impairment based on cognitive, neuropsychiatric and functional features: analysis of data from the National Alzheimer's Coordinating Center. (2011) (34)
Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia (2019) (34)
Muscarinic acetylcholine receptor immunoreactivity after hippocampal commissural/associational pathway lesions: Evidence for multiple presynaptic receptor subtypes (1997) (34)
Paraoxonase-1 polymorphisms in Alzheimer's disease, Parkinson's disease, and AD-PD spectrum diseases (2012) (34)
CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease? (2014) (33)
Identification of Conserved Proteomic Networks in Neurodegenerative Dementia (2019) (33)
m2 Muscarinic receptor immunolocalization in cholinergic cells of the monkey basal forebrain and striatum (1999) (33)
Radioligand binding and immunoautoradiographic evidence for a lack of toxicity to dopaminergic nerve terminals in human cocaine overdose victims (1997) (33)
Elongation Factor 1A Family Regulates the Recycling of the M4 Muscarinic Acetylcholine Receptor (2006) (32)
PARK10 Candidate RNF11 Is Expressed by Vulnerable Neurons and Localizes to Lewy Bodies in Parkinson Disease Brain (2007) (32)
Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease (2013) (32)
Aggregation Properties of the Small Nuclear Ribonucleoprotein U1-70K in Alzheimer Disease* (2014) (32)
Distribution of muscarinic cholinergic receptor proteins m1 to m4 in area 17 of normal and monocularly deprived rhesus monkeys (1997) (31)
Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease (2020) (31)
Functional downregulation of GluR2 in piriform cortex of kindled animals (2000) (31)
Genetic control of the human brain proteome (2019) (31)
Merger of laser capture microdissection and mass spectrometry: a window into the amyloid plaque proteome. (2006) (31)
LIM kinase 1 accumulates in presynaptic terminals during synapse maturation (2000) (30)
Racial Disparity in Cognitive and Functional Disability in Hypertension and All-Cause Mortality. (2016) (30)
Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells. (2002) (29)
Subpopulations of rat dorsal root ganglion neurons express active vesicular acetylcholine transporter (2004) (29)
Diffuse Plaques in the Striatum in Alzheimer Disease (AD): Relationship to the Striatal Mosaic and Selected Neuropeptide Markers (1997) (29)
Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer's disease. (2014) (28)
A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease (2021) (28)
RNF11 modulates microglia activation through NF-κB signalling cascade (2012) (27)
CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease (2016) (27)
Immunolocalization of muscarinic acetylcholine subtype 2 receptors in rat cochlear nucleus (1996) (27)
Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau (2020) (26)
Transcriptional regulation of homeostatic and disease‐associated‐microglial genes by IRF1, LXRβ, and CEBPα (2019) (26)
White matter hyperintensities and changes in white matter integrity in patients with Alzheimer’s disease (2011) (26)
Author Correction: Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (26)
Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease (2021) (25)
Inflammation and cognitive functioning in African Americans and Caucasians (2015) (25)
Seizures following myelography with iopamidol (1988) (25)
Abnormal gephyrin immunoreactivity associated with Alzheimer disease pathologic changes. (2013) (25)
Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial. (2021) (24)
Mint3/X11gamma is an ADP-ribosylation factor-dependent adaptor that regulates the traffic of the Alzheimer's Precursor protein from the trans-Golgi network. (2008) (24)
Sequestration of Muscarinic Cholinergic Receptors in Permeabilized Neuroblastoma Cells (1994) (24)
Light-microscopic distribution and parasagittal organisation of muscarinic receptors in rabbit cerebellar cortex (1995) (24)
White Matter Integrity and Episodic Memory Performance in Mild Cognitive Impairment: A Diffusion Tensor Imaging Study (2009) (24)
Integrated Approaches for Analyzing U1-70K Cleavage in Alzheimer’s Disease (2014) (24)
The State of Systems Genetics in 2017. (2017) (24)
Association Between Angiotensin Receptor Blockers and Longitudinal Decline in Tau in Mild Cognitive Impairment. (2015) (24)
Coordinate Expression of the Vesicular Acetylcholine Transporter and Choline Acetyltransferase Following Septohippocampal Pathway Lesions (1998) (23)
TREM 2 is associated with increased risk for Alzheimer ' s disease in African Americans (23)
NF-κB activity is inversely correlated to RNF11 expression in Parkinson's disease (2013) (23)
Differential effects of allosteric M(1) muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation. (2010) (23)
Cloning and Localization of Exon 5‐Containing Isoforms of the NMDAR1 Subunit in Human and Rat Brains (1997) (22)
Viscoelastic Properties of Human Autopsy Brain Tissues as Biomarkers for Alzheimer's Diseases (2019) (22)
Extracellular signal‐regulated kinase regulates microglial immune responses in Alzheimer’s disease (2021) (22)
18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery (2018) (21)
Rationale and Design of the Emory Healthy Aging and Emory Healthy Brain Studies (2019) (21)
The Relationship Between Cognitive Functioning and the JNC-8 Guidelines for Hypertension in Older Adults (2017) (21)
Neurobiologic Rationale for Treatment of Apathy in Alzheimer’s Disease With Methylphenidate (2020) (20)
Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features (2017) (20)
Proteomic Analysis of Hippocampal Dentate Granule Cells in Frontotemporal Lobar Degeneration: Application of Laser Capture Technology (2011) (20)
Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease (2019) (20)
KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease (2021) (19)
Evidence of shared risk for Alzheimer’s disease and Parkinson’s disease using family history (2007) (19)
A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data (2019) (19)
Immunohistochemical Localization of Proteins in the Nervous System (2003) (19)
Comparative distribution of protein components of the A20 ubiquitin-editing complex in normal human brain (2012) (19)
VisMET: a passive, efficient, and sensitive assessment of visuospatial memory in healthy aging, mild cognitive impairment, and Alzheimer's disease (2019) (18)
ADP-RIBOSYLATION FACTOR-DEPENDENT COAT PROTEINS THAT REGULATE THE TRAFFIC OF -ALZHEIMER'S PRECURSOR PROTEIN* (2003) (17)
Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease (2021) (17)
Progress with Treatments for Alzheimer's Disease. (2021) (17)
Shared mechanisms across the major psychiatric and neurodegenerative diseases (2022) (16)
Mint 3 / X 11 Is an ADP-Ribosylation Factor-dependent Adaptor that Regulates the Traffic of the Alzheimer ’ s Precursor Protein from the Trans-Golgi Network (2007) (16)
Characterization of Detergent Insoluble Proteome in Chronic Traumatic Encephalopathy (2018) (16)
Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways (2016) (16)
Neuronal RING finger protein 11 (RNF11) regulates canonical NF-κB signaling (2012) (16)
Large‐scale deep multi‐layer analysis of Alzheimer’s disease brain reveals strong proteomic disease‐related changes not observed at the RNA level (2021) (16)
Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status (2021) (16)
Evidence for the presence of muscarinic M2 and M4 receptors in guinea-pig gallbladder smooth muscle. (1998) (15)
Purpose in life is a robust protective factor of reported cognitive decline among late middle-aged adults: The Emory Healthy Aging Study. (2019) (15)
Striatal dopamine nerve terminal markers but not nigral cellularity are reduced in spinocerebellar ataxia type 1 (1997) (15)
Unique molecular characteristics and microglial origin of Kv1.3 channel–positive brain myeloid cells in Alzheimer’s disease (2021) (15)
Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia (2018) (15)
Network Analysis of a Membrane-Enriched Brain Proteome across Stages of Alzheimer’s Disease (2019) (15)
Destruction of Midbrain Dopaminergic Neurons by Using Immunotoxin to Dopamine Transporter (2003) (15)
Potassium Channel Kv 1 . 3 Is Highly Expressed by Microglia in Human Alzheimer ' s Disease (2015) (14)
Aberrant septin 11 is associated with sporadic frontotemporal lobar degeneration (2011) (14)
Neurocognitive correlates of nocturnal oxygen desaturation in a memory clinic population (2012) (14)
Association of GSK 3 B With Alzheimer Disease and Frontotemporal Dementia (2008) (14)
Hippocampal place cell dysfunction and the effects of muscarinic M1 receptor agonism in a rat model of Alzheimer's disease (2018) (13)
RING finger protein 11 (RNF11) modulates susceptibility to 6-OHDA-induced nigral degeneration and behavioral deficits through NF-κB signaling in dopaminergic cells (2013) (13)
The regulation of presenilin‐1 by nerve growth factor (2001) (13)
Neuronal LR11 Expression Does Not Differentiate between Clinically-Defined Alzheimer's Disease and Control Brains (2012) (13)
Multiscale causal network models of Alzheimer’s disease identify VGF as a key regulator of disease (2018) (12)
The impact of vascular comorbidities on qualitative error analysis of executive impairment in Alzheimer’s disease (2009) (12)
Synthesis and In Vitro Evaluation of Imidazo[1,2-b]pyridazines as Ligands for β-Amyloid Plaques. (2010) (12)
Geographical Differences in the Occurrence of Alzheimer's Disease Mortality: United States Versus Puerto Rico (2008) (12)
A semi-mechanism approach based on MRI and proteomics for prediction of conversion from mild cognitive impairment to Alzheimer’s disease (2016) (12)
Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study (2021) (12)
Is ApoE &egr;4 Associated with Cognitive Functioning in African Americans Diagnosed with Alzheimer Disease? An Exploratory Study (2009) (11)
A 'Framingham-like' Algorithm for Predicting 4-Year Risk of Progression to Amnestic Mild Cognitive Impairment or Alzheimer's Disease Using Multidomain Information. (2018) (11)
Deep Convolutional Neural Networks and Transfer Learning for Measuring Cognitive Impairment Using Eye-Tracking in a Distributed Tablet-Based Environment (2020) (11)
REDLetr: Workflow and tools to support the migration of legacy clinical data capture systems to REDCap (2016) (11)
The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum (2016) (10)
Feedforward prediction error signals during episodic memory retrieval (2020) (10)
Targeted Quantification of Detergent-Insoluble RNA-Binding Proteins in Human Brain Reveals Stage and Disease Specific Co-aggregation in Alzheimer’s Disease (2021) (10)
Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease (2022) (9)
A PROOF OF CONCEPT PHASE II STUDY REPURPOSING ATOMOXETINE FOR NEUROPROTECTION IN MILD COGNITIVE IMPAIRMENT: EVIDENCE FOR TARGET ENGAGEMENT, REGULATION OF CSF BIOMARKERS, AND DISEASE-MODIFYING POTENTIAL (2019) (9)
FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2020) (9)
Effects of Selective M1 Muscarinic Receptor Activation on Hippocampal Spatial Representations and Neuronal Oscillations. (2016) (9)
Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer’s disease (2021) (9)
Atlas of RNA editing events affecting protein expression in aged and Alzheimer’s disease human brain tissue (2021) (9)
Reply: LATE to the PART-y. (2019) (8)
TBK1 interacts with tau and enhances neurodegeneration in tauopathy (2020) (8)
Multi-platform proteomic analysis of Alzheimer’s disease cerebrospinal fluid and plasma reveals network biomarkers associated with proteostasis and the matrisome (2022) (8)
Microglial ERK activation is a critical regulator of pro-inflammatory immune responses in Alzheimer’s disease (2019) (8)
Automated analysis of facial emotions in subjects with cognitive impairment (2022) (8)
Generation of transporter-specific antibodies. (1998) (8)
Cell type-specific biotin labeling in vivo resolves regional neuronal and astrocyte proteomic differences in mouse brain (2022) (8)
A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensamble and on multivariate algorithms, to characterize late onset Alzheimer’s disease (2020) (8)
Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization (2021) (7)
MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS (2017) (7)
Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease (2021) (7)
Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. (2020) (7)
Mass Spectrometry-Based Quantification of Tau in Human Cerebrospinal Fluid Using a Complementary Tryptic Peptide Standard. (2019) (7)
CSF and Neuropsychological Correlates of Visual Hallucination in Dementia with Lewy Bodies (2014) (7)
A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease (2022) (7)
Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease (2022) (6)
Predictive Model for Early Detection of Mild Cognitive Impairment and Alzheimer’s Disease (2013) (6)
Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume (2022) (6)
Genetic Evidence Supporting a Causal Role of Depression in Alzheimer’s Disease (2021) (6)
Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference (2018) (6)
[20] Anti-fusion protein antibodies specific for receptor subtypes (1995) (6)
Cloning of M‐calpain 80 kD subunit from the axonal degeneration‐resistant WLDs mouse mutant (1998) (6)
Molecules of the Brain (2000) (6)
Predicting Alzheimer’s disease progression using multi-modal deep learning approach (2019) (6)
The landscape of metabolic brain alterations in Alzheimer’s disease (2021) (5)
U1 small nuclear ribonucleoproteins (snRNPs) aggregate in Alzheimer’s disease due to autosomal dominant genetic mutations and trisomy 21 (2014) (5)
Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias (2021) (5)
Integrating human brain proteomes with genome-wide association data implicates novel proteins in post-traumatic stress disorder (2022) (5)
Alzheimer disease risk factors. (2014) (5)
Frequency of the TREM2 R47H Variant in Various Neurodegenerative Disorders (2019) (5)
Association of plasma and CSF cytochrome P450, soluble epoxide hydrolase, and ethanolamide metabolism with Alzheimer’s disease (2021) (5)
The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (5)
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease (2022) (5)
Signatures of glial activity can be detected in the CSF proteome (2022) (5)
Alzheimer’s disease and progressive supranuclear palsy share similar transcriptomic changes in distinct brain regions (2021) (5)
Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients (2022) (4)
Mental stress-induced myocardial ischemia and cognitive impairment in coronary atherosclerosis. (2020) (4)
Manifestations of Alzheimer’s disease genetic risk in the blood are evident in a multiomic analysis in healthy adults aged 18 to 90 (2022) (4)
Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts (2016) (4)
CSF proteome profiling across the Alzheimer’s disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels (2022) (4)
Assessment of cholesterol homeostasis in the living human brain (2022) (4)
A systems pharmacology-based approach to identify novel Kv1.3 channel-dependent mechanisms in microglial activation (2017) (4)
Hypertension and Alzheimer disease: is there a link? (2012) (3)
Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease (2022) (3)
Phenylephrine and norepinephrine increase dopamine transporter ligand binding in striatum. (2003) (3)
Brain microRNAs associated with late-life depressive symptoms are also associated with cognitive trajectory and dementia (2020) (3)
142nd Annual Meeting of the American Neurological Association (1978) (3)
Chronically mad as a hatter: Anticholinergics and Alzheimer's disease pathology (2003) (3)
Priorities for research on neuromodulatory subcortical systems in Alzheimer's disease: Position paper from the NSS PIA of ISTAART. (2023) (3)
The Feasibility of Measuring Gait in an Outpatient Cognitive Neurology Clinical Setting. (2019) (3)
Informed Consent in Two Alzheimer’s Disease Research Centers: Insights From Research Coordinators (2020) (3)
Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (3)
Functional Screening of Drug Target Genes (2004) (3)
Cerebral atherosclerosis contributes to Alzheimer’s dementia independently of its hallmark amyloid and tau pathologies (2019) (3)
Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease (2020) (3)
Synthesis and evaluation of two 18F-labeled imidazo[1,2-a]pyridine analogues as potential agents for imaging beta-amyloid in Alzheimer's disease. (2006) (3)
Functional screening of drug target genes: m1 muscarinic acetylcholine receptor phenotypes in degenerative dementias. (2004) (2)
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. (2021) (2)
Proteomic analysis of the poly‐ubiquitin profiles in Alzheimer's Disease (2019) (2)
Common pattern of deficit in multinational MCI cohort identified by objective computerized cognitive assessment (2005) (2)
Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R (2020) (2)
Quantitative proteomics of acutely-isolated mouse microglia identifies novel immune Alzheimer’s disease-related proteins (2018) (2)
A Genetic Study of Cerebral Atherosclerosis Reveals Novel Associations with NTNG1 and CNOT3 (2021) (2)
Immunization for Alzheimer's disease: A shot in the arm or a whiff? (2000) (2)
P1-130 The “Mini-cog” as a screen for dementia: validation in an African American population (2004) (2)
Brain microRNAs are associated with variation in cognitive trajectory in advanced age (2019) (2)
Cerebral Aβ deposition in an Aβ-precursor protein-transgenic rhesus monkey (2022) (2)
CO‐registration of proton magnetic resonance spectroscopy (1H‐MRS) and diffusion imaging (DMRI) in healthy aging: A prospective study of cerebral neurochemistry and microstructure (2020) (2)
Neuronal RING finger protein 11 (RNF11) regulates canonical NF-κB signaling (2012) (2)
Mint3/X11 gamma is an ADP-ribosylation factor-dependent adaptor that regulates the traffic of the Alzheimer's precursor protein from the trans-Golgi network (2)
DOPAMINE RECEPTORS IN THE BASAL GANGLIA OF THE RAT : LIGHT AND ELECTRON MICROSCOPY (2003) (2)
Renin-Angiotensin-System Modulation may slow the Conversion from Mild Cognitive Impairment to Alzheimer’s Disease (2016) (2)
Association between Symptoms of Psychological Distress and Cognitive Functioning among Adults with Coronary Artery Disease. (2020) (2)
Immunochemical analysis of dopamine transporters in Parkinson's disease. (2001) (2)
P1-075 Behavioral tasks and eye-tracking technology for early diagnosis of Alzheimer's disease in patients with mild cognitive impairment (MCI) (2004) (1)
Machine Learning Selection of Most Predictive Brain Proteins Suggests Role of Sugar Metabolism in Alzheimer’s Disease (2023) (1)
Integrating human brain proteomes and genome‐wide association results implicates new genes in Alzheimer’s disease (2020) (1)
Racial‐ethnic differences in baseline and longitudinal change in neuropsychological test scores in the NACC Uniform Data Set 3.0 (2021) (1)
Vesicular monoamine transporter immunoreactivity is reduced in Parkinsons diseased striatum (1996) (1)
Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease (2013) (1)
Erratum: Complex relationship between Parkin mutations and Parkinson disease (American Journal of Medical Genetics-Neuropsychocetric (2002) 114-(584-591)) (2002) (1)
Predicting the onset of Alzheimer's disease with a behavioral task (2011) (1)
Author Correction: Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease (2021) (1)
Alzheimer's disease genetic burden is associated with mid‐life depression among persons with normal cognition (2022) (1)
Targeting the Moesin‐CD44 pathway for therapeutic intervention in Alzheimer’s disease (2020) (1)
Depression contributes to Alzheimer’s disease through shared genetic risk (2021) (1)
Higher arterial stiffness but not blood pressure is associated with brain amyloidosis and preclinical AD in healthy adults: Results from the Emory Healthy Brain Study (2020) (1)
Cell type-specific biotin labeling in vivo resolves regional neuronal proteomic differences in mouse brain (2021) (1)
Production of Antisera Using Fusion Proteins (1997) (1)
FEASIBILITY OF AMBULATORY OVERNIGHT OXIMETRY IN CONSECUTIVE PATIENTS IN A DEMENTIA CLINIC (2005) (1)
LDL cholesterol is associated with higher AD neuropathology burden independent of APOE (2022) (1)
Erratum: Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. (Brain (2019) 142, (1503–1527) DOI: 10.1093/brain/awz099) (2019) (1)
The 5th International Conference on Molecular Neurodegeneration: Overlapping Pathologies and Common Mechanisms (2019) (1)
Quantitative multiplexed proteomics of mouse microglia by flow-cytometric sorting reveals a core set of highly-abundant microglial proteins (2019) (1)
TREM2 is associated with increased risk for Alzheimer’s disease in African Americans (2015) (1)
Large-scale proteomic analysis of human brain identifies proteins associated with cognitive trajectory in advanced age (2019) (1)
Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer’s disease (2020) (1)
Behavioral performance as a predictor of cognitive decline: Detecting the transition from healthy aging to mild cognitive impairment (2012) (1)
the Risk of Myocardial Infarction A Common Variant on Chromosome 9 p 21 Affects (2008) (1)
Cognitive Empowerment Program for Individuals with Mild Cognitive Impairment: Description and Preliminary Satisfaction Ratings (2020) (1)
Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease (2013) (1)
Erratum: Infracortical interstitial cells concurrently expressing m2- muscarinic receptors, acetylcholinesterase and nicotinamide adenine dinucleotide phosphate-diaphorase in the human and monkey cerebral cortex (Neuroscience (1998) 84 (755-769)) (1998) (1)
Examination of the reliability and feasibility of two smartphone applications to assess executive functioning in racially diverse older adults (2021) (1)
Certain antihypertensives may slow the conversion from mild cognitive impairment to Alzheimer’s disease (2015) (1)
Elevated serum DDE and risk for Alzheimer disease--reply. (2014) (1)
Polymer-Encapsulated PC-12 Cells Demonstrate High-Affinity Uptake of Dopamine in Vitro and 18F-DOPA Uptake and Metabolism after Intracerebral Implantation in Nonhuman Primates (1997) (1)
Global quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer’s disease (2020) (1)
AMultiancestral Genome-Wide Exome Array Study of Alzheimer Disease , Frontotemporal Dementia , and Progressive Supranuclear Palsy (2015) (1)
THE ACUTE PHASE PROTEIN ALPHA-2-MACROGLOBULIN PREDICTS RISK OF INCIDENT ALZHEIMER'S DISEASE AND MODULATES TAU PATHOLOGY THROUGH THE RCAN1-CALCINEURIN PATHWAY (2016) (0)
Evidence for dose-dependent neurotoxicity of amyloid-β oligomers/Aβ-derived diffusible ligands generated from physiological processing of transgenic human APP in situ in mouse brain (2010) (0)
Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) (0)
Cholinergic and neurotrophic markers within the nucleus basalis in elderly individuals with mild cognitive impairment and early Alzheimer's disease (2000) (0)
P1-170: Non-verbal memory performance is associated with conversion to dementia within one year: A prospective study of mild cognitive impairment using computerized cognitive assessment (2008) (0)
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia (2018) (0)
First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer’s disease: the Dominantly Inherited Alzheimer’s Network Study (2022) (0)
Analysis of the functional role of endosomal presenilin-1 (2000) (0)
FUNCTIONAL GENETIC DISSECTION OF AN ALZHEIMER’S DISEASE SUSCEPTIBILITY NETWORK (2018) (0)
BRAIN MICRORNAS ASSOCIATED WITH LATE-LIFE DEPRESSION ARE ALSO LINKED TO COGNITIVE TRAJECTORY AND DEMENTIA (2019) (0)
Ftld-tdp to Tau Ratio Is a Biomarker for 181 Reduced Csf P-tau (0)
S3-04-02: Muscarinic acetylcholine receptor subtype regulation of amyloid precursor protein processing (2008) (0)
Correction to: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer’s disease (2021) (0)
Additional file 1: Table S1. of CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease (2016) (0)
REGULATION OF PRO-INFLAMMATORY AND DISEASE-ASSOCIATED MICROGLIAL ACTIVATION BY BIN1 (2019) (0)
Molecules of senescent glial cells differentiate Alzheimer’s disease from ageing (2023) (0)
A matrisomal proteomics network modulates tau and amyloid‐beta toxicity in fly AD models. (2022) (0)
Tool and chemical probe development for emerging targets in Alzheimer’s disease: The Emory‐Sage‐SGC TREAT‐AD Center (2021) (0)
Protein co-expression network analysis in Alzheimer’s disease (2015) (0)
Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer’s disease (2018) (0)
Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
Proteome-wide discovery of cortical proteins that may provide motor resilience to offset the negative effects of pathologies in older adults. (2022) (0)
FUNCTIONAL DISSECTION OF AN ALZHEIMER’S DISEASE SUSCEPTIBILITY GENE NETWORK (2019) (0)
SORTOUT‐AB: A Study of Race to Understand Alzheimer Biomarkers (2022) (0)
Muscarinic activation of MAPK in PC12 cells (1999) (0)
P2-246 APOE4 genotype and sleep apnea in Alzheimer's disease: initial studies (2004) (0)
Stimulation of muscarinic receptors in vivo induces dramatic modifications of the subcellular distribution of the m2 muscarinic receptor in striatal interneurons (1998) (0)
Integration of proteomics and metabolomics - insights into inflammation, metabolic dysregulation, and vascular aspects in AD (2022) (0)
Author Correction: Multimodal hippocampal subfield grading for Alzheimer’s disease classification (2020) (0)
Friday, March 16, 2007. pp. 97–134 (2007) (0)
Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease (2020) (0)
P1-023 Functional abilities in patients with mild cognitive impairment versus Alzheimer's disease and normal controls (2004) (0)
Response to Buslovich and Colleagues (2014) (0)
Neurobiological Pathways Linking Acute Mental Stress to Impairments in Executive Function in Individuals with Coronary Artery Disease (2021) (0)
Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer’s disease (2022) (0)
DO EPIGENETIC AND TRANSCRIPTOMIC PATTERNS EXPLAIN THE ASSOCIATION BETWEEN LATE-LIFE DEPRESSION AND INCREASED RISK FOR DEMENTIA? (2019) (0)
p3-Alc peptides produced by covariant processing of Alcadein and APP implicate γ-secretase dysfunction in sporadic Alzheimer's disease (2009) (0)
Human Brain Proteome-Wide Association Study of Depression Identified 24 Proteins as Tractable Targets for Further Mechanistic Studies (2020) (0)
SEX-SPECIFIC PROTEIN DIFFERENCES LINKED TO ALZHEIMER’S DISEASE RISK UNCOVERED BY A COEXPRESSION-REGRESSION FRAMEWORK (2019) (0)
Novel proteomic molecular signatures of brain endothelial cells and microglia in the aging mouse brain (2020) (0)
Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) (0)
Publisher Correction: Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain (2020) (0)
Early-onset Alzheimer's disease likely has autosomal recessive causes (2011) (0)
Molecular and behavioral phenotypes caused by selective disruption of M4 muscarinic acetylcholine receptors in D1 dopamine receptor‐expressing cells (2008) (0)
The Georgia Memory Net: Implementation of a statewide program to diagnose and treat Alzheimer's disease and related dementias (2022) (0)
P3-057 The impact of vascular risk on concept formation in Alzheimer’s disease (2006) (0)
Tau phosphosignatures discriminate Alzheimer Disease from other tauopathies (2015) (0)
P2-181 A prospective study of cognitive performance in amnestic MCI using comprehensive computerized assessment (2006) (0)
RNA-BINDING PROTEINS WITH MIXED CHARGE DOMAINS SELF-ASSEMBLE AND AGGREGATE IN ALZHEIMER'S DISEASE (2018) (0)
DEVELOPING AN ELECTRONIC CONSENT FOR ADRC HIGH COMPLIANCE, CONTINUOUS LONG-TERM HOME MONITORING OF SLEEP ACTIVITY IN DIVERSE POPULATIONS DIFFERENTIATES LOWER COGNITIVE FUNCTIONING OLDER ADULTS (2019) (0)
O4-09-03 IMMUNOSUPPRESSION EXACERBATES ALZHEIMER’S DISEASE PATHOLOGY IN APP/PS1 TRANSGENIC MICE (2019) (0)
P3-295 Quantification of LR11 expression in mild cognitive impairment, a human model for early Alzheimer's disease (2004) (0)
Proteomics of protein post-translational modifications implicated in neurodegeneration (2014) (0)
The location of PSEN1 pathogenic variants in transmembrane vs. cytoplasmic domains may alter neurodegenerative and cognitive trajectories: Findings from the DIAN study (2021) (0)
Diabetes-linked SORCS1, a gamma-secretase substrate and regulator of Alzheimer APP metabolism, forms complexes with multiple Alzheimer-linked proteins (APP, PS1, BACE, VPS35, and SORLA) (2010) (0)
Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) (0)
MOLECULAR AND OMICS-BASED ANALYSES ATRANSCRIPTOMIC LANDSCAPE OF MICROGLIAL ACTIVATION IN ALZHEIMER’S DISEASE (2018) (0)
Unbiased Classification of the Human Brain Proteome Resolves Distinct Clinical and Pathophysiological Subtypes of Cognitive Impairment (2022) (0)
PROTEIN CO-EXPRESSION NETWORK ANALYSIS IN ASYMPTOMATIC AND SYMPTOMATIC ALZHEIMER'S DISEASE (2017) (0)
A blood-based signature of cerebrospinal fluid Aβ1–42 status (2019) (0)
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains. (2022) (0)
genetic Alzheimer’s disease Integrating human brain proteomes and genome-wide association results implicates new genes in Alzheimer’s disease (2020) (0)
A TRANSCRIPTOMIC LANDSCAPE OF MICROGLIAL ACTIVATION IN ALZHEIMER’S DISEASE (2018) (0)
P3-303 Examining the role of the APOE receptor LR11 in the etiopathology of Alzheimer's disease (2004) (0)
Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation (2020) (0)
CSF protein panels reflecting multiple pathophysiological mechanisms for early and specific diagnosis of Alzheimer’s disease (2021) (0)
Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2022) (0)
O2-02-05 RNA-BINDING PROTEINS WITH MIXED CHARGEDOMAINS SELF-ASSEMBLE AND AGGREGATE IN ALZHEIMER’S DISEASE (2018) (0)
Davos Alzheimer’s Collaborative: Building a globally representative cohort through a technologically‐enabled approach (2022) (0)
CSF complement 3 and factor H are staging biomarkers in Alzheimer’s disease (2016) (0)
Phenotypic Differences In Cholinergic Markers Within The Nucleus Basalis In Individuals With Mild Cognitive Impairment (2002) (0)
Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (0)
Apathy in Dementia Methylphenidate Trial 2 (ADMET2): Results of a phase III, placebo‐controlled, double‐blind, 6‐month, multi‐center, randomized clinical trial (2021) (0)
Correction to: Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer’s disease (2021) (0)
Mutual inhibition between the notch and WNT signalling pathways in mammalian cell lines (2002) (0)
Brain phosphoproteome network analysis discriminates Alzheimer's disease from other tauopathies (2015) (0)
Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial (2022) (0)
A longitudinal study of gait on fall risk and disease progression in patients with mild cognitive impairment and Alzheimer's disease (2020) (0)
Erratum (1979) (0)
1 OXIDATIVE MODIFICATIONS AND AGGREGATION OF Cu / Zn SUPEROXIDE DISMUTASE ASSOCIATED WITH ALZHEIMER ' S AND PARKINSON ' S DISEASES * (2004) (0)
PROTEOMIC NETWORK ANALYSIS TO FIND COMMON MECHANISMS UNDERLYING ALZHEIMER'S DISEASE AND PD (2016) (0)
Fine particulate air pollution and neuropathology markers of Alzheimer’s disease in donors with and without APOE ε4 alleles – results from an autopsy cohort (2023) (0)
TAU CYTOPATHOLOGY IN A PATIENT WITH FAMILIAL EARLY ONSET DEMENTIA (1998) (0)
P4-143 Identification of the apoe receptor sorLA/LR11 as a novel component of hallmark Alzheimer’s disease-related lesions in down syndrome (2006) (0)
AND PROTEOMICS INTEGRATIVE PROTEOMICS LINKS CEREBROSPINAL FLUID BIOMARKERS TO PATHOLOGICAL NETWORKS IN THE ALZHEIMER’S DISEASE BRAIN HIPPOCAMPAL ATROPHY (2019) (0)
Podium Presentations: Wednesday, July 25, 2018 P1394 F4-07-04 THE CONSEQUENCES OF TAU IN THE LOCUS COERULEUS ON ALZHEIMER’S DISEASE (2018) (0)
DISCOVERY OF NOVEL PROTEOMIC TARGETS FOR TREATMENT OF ALZHEIMER'S DISEASE (2016) (0)
RNA-binding proteins with mixed charge domains self-assemble and aggregate in Alzheimer’s Disease (2018) (0)
P-073: Elevated Serum Levels of p,pʼ-DDE are Associated with Increased Risk for Alzheimerʼs Disease (2012) (0)
Increased Expression Of Kv1.3 Channels By Microglia In Alzheimer’s Disease (P1.240) (2014) (0)
INTEGRATED PROTEOMICS AND PHOSPHOPROTEOMICS REVEAL NETWORKS LINKED TO ALZHEIMER’S DISEASE RISK (2018) (0)
A Retrospective Study of Progressive Gait Impairment in Alzheimer’s Disease (2022) (0)
Synthesis and Evaluation of Two 18F-Labeled Imidazo[1,2-a]pyridine Analogues as Potential Agents for Imaging β-Amyloid in Alzheimer′s Disease. (2006) (0)
P-003 An eight minute time limit increases sensitivity and improves clinical utility of the folstein mini mental state exam in african americans (2007) (0)
DEVELOPING AN ELECTRONIC CONSENT FOR ADRC (2019) (0)
Cerebrospinal Fluid beta-Amyloid 1-42 Solubility Is Influenced by Apolipoproteins E and J (S14.002) (2012) (0)
Progressive white matter injury in autosomal dominant Alzheimer’s disease is strongly associated with cerebral microbleeds and neurodegeneration (2022) (0)
KV1.3 INHIBITION REDUCES AB-INDUCED MICROGLIAL NEUROTOXICITY (2016) (0)
P3-055 The role of specific vascular biomarkers on executive functioning in Alzheimer’s disease (2006) (0)
Identifying novel causal genes and proteins in Alzheimer’s disease (2020) (0)
ELUCIDATING THE RELATIONSHIP BETWEEN HYPERPHOSPHORYLATED TAU AND LOCUS COERULEUS DEGENERATION IN ALZHEIMER’S DISEASE (2016) (0)
Medical Management of the Surgical Patient: Management of the surgical patient with dementia (2006) (0)
P1-115 Characterization of PS1/APP mice deficient for the ApoE receptor sorLA/LR11 (2006) (0)
DISTINCT BASELINE AND STRESS-INDUCED MAPK SIGNALING RESPONSES CHARACTERIZE MICROGLIA IN ALZHEIMER’S DISEASE MODELS (2019) (0)
Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration (2020) (0)
Differential Gene Expression in Microglial Polarized States and in Alzheimer’s Disease: Novel Insights Provided by Weighted Correlation Network Analysis (WGCNA) (P4.011) (2016) (0)
LSD1 protects against hippocampal and cortical neurodegeneration (2017) (0)
Advances in the molecular neurobiology of Alzheimerʼs disease (1992) (0)
Diversity of mAChR heteroreceptor proteins in multiple hippocampal circuits (1997) (0)
AGE RELATED CHANGES IN DOPAMINE TRANSPORTER IMMUNOREACTIVITY WITHIN THE HUMAN SUBSTANTIA NIGRA: AN UNBIASED STEREOLOGIC EVALUATION (1998) (0)
Production of Antisera Using Fusion Proteins (1997) (0)
Integrating multimodal data to support Alzheimer’s disease target prioritization (2021) (0)
Multiscale network modeling of oligodendrocytes reveals molecular components of myelin dysregulation in Alzheimer’s disease (2017) (0)
41-1: Subtype-specific muscarinic cholinergic therapies in Alzheimer's disease (1997) (0)
GenEpi: gene-based epistasis discovery using machine learning (2020) (0)
The trend of disruption in the functional brain network topology of Alzheimer’s disease (2021) (0)
LARGE-SCALE PROTEOMIC ANALYSIS OF HUMAN PREFRONTAL CORTEX IDENTIFIES PROTEINS ASSOCIATED WITH COGNITIVE TRAJECTORY IN ADVANCED AGE (2019) (0)
INTEGRATIVE PROTEOMICS LINKS CEREBROSPINAL FLUID BIOMARKERS TO PATHOLOGICAL NETWORKS IN THE ALZHEIMER’S DISEASE BRAIN (2019) (0)
The Collaboration and Harmonization of Digital Biomarkers for Alzheimer’s Research (2022) (0)
Syddansk Universitet Variant ASGR1 associated with a reduced risk of coronary artery disease (2016) (0)
Editorial Board (2007) (0)
Complement Factor H is a Biomarker for Mild Cognitive Impairment Not Due to Alzheimer’s Disease (I11-1.006) (2014) (0)
COMPREHENSIVE MAPPING OF ALZHEIMER’S DISEASE BRAIN UBIQUITYLOME (2018) (0)
A CSF Signature of Frontotemporal Lobar Degeneration with C9orf72 Repeat Expansions (S18.003) (2014) (0)
Use of specific antibodies for studying mGluR subtypes in rat brain (1996) (0)
The Collaboration and Harmonization of Digital Biomarkers for Alzheimer’s Research (2022) (0)
Pathologic Aggregates Of Small Nuclear Ribonucleoproteins (snRNP) Are Present In Familial Alzheimer's Disease (P1.244) (2014) (0)
Gross Effects on the Nervous System References Cited (0)
AD‐causing variants that affect PSEN1 transmembrane domains are associated with faster neurodegeneration and cognitive decline compared to those affecting cytoplasmic domains (2022) (0)
Why We Need an Alzheimer's Moonshot in 2022 (2022) (0)
Detection Of Increased Transcripts Of Human Endogenous Retrovirus In Plasma Of Patients With Frontotemporal Dementia Associated Amyotrophic Lateral Sclerosis (S40.004) (2014) (0)
Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer’s disease (2020) (0)
Guinea-pig tracheal parasympathetic nerves in primary culture express M2 muscarinic receptors (1995) (0)
Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction (2023) (0)
Proteomics identifies CSF biomarker panels reflective of pathological networks in the Alzheimer's disease brain (2020) (0)
Reply (2000) (0)
Reply (1991) (0)
P3-300 Effect of targeted domain deletions on LR11-mediated regulation of extracellular Aβ levels (2004) (0)
The Emory‐Sage‐SGC TREAT‐AD Center: Tool and probe development for emerging targets in Alzheimer’s Disease (2022) (0)
PRODUCTION OF MONOCLONAL ANTIBODIES REACTIVE AGAINST CHOLINE ACETYLTRANSFERASE AND THEIR APPLICATION FOR STUDYING CHOLINERGIC SYSTEMS. (1985) (0)
Equity and Engagement for Neurologic Research Participation at the Goizueta Alzheimer’s Disease Research Center of Emory University (2022) (0)
Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty (2017) (0)
Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease (2018) (0)
Proteomics Discovery of New Alzheimer’s Disease Targets (2015) (0)
Effects of candesartan vs. lisinopril on neurocognitive functioning in executive mild cognitive impairment: The CALIBREX trial (2020) (0)
Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia (2018) (0)
THE CONSEQUENCES OF TAU IN THE LOCUS COERULEUS ON ALZHEIMER'S DISEASE (2018) (0)
Multimodal magnetic resonance imaging reveals distinct sensitivity of hippocampal subfields in asymptomatic stage of Alzheimer’s disease (2022) (0)
Rare sequence variants that disrupt ASGR 1 function lower non-HDL cholesterol and protect against coronary artery disease (2016) (0)
Asparagine endopeptidase cleaves amyloid precursor protein and promotes amyloidogenesis in Alzheimer's disease (2015) (0)
Operational criteria for patient recruitment in trials of mild cognitive impairment (2005) (0)
Functional Analyses of Genetic Risk Variants of Depression-Related Phenotypes in the Human Brain (2020) (0)
Abstract P021: Association of AHA Cardiovascular Health Metrics With Cognitive Function, Depression, and Anxiety: The Emory Healthy Aging Study (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Allan I. Levey?

Allan I. Levey is affiliated with the following schools:

Yale University
Emory University
Case Western Reserve University

Allan I. Levey's Academic­Influence.com Rankings

Why Is Allan I. Levey Influential?

Allan I. Levey's Published Works

Published Works

What Schools Are Affiliated With Allan I. Levey?

Allan I. Levey's AcademicInfluence.com Rankings